A Study to Evaluate Smartphone-based Digital Phenotyping for Relapse Prediction in Alcohol-associated Liver Disease

Overview

Información sobre este estudio

The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients with alcohol-associated liver disease.

The secondary aim of this study is to assess the relationship between this digital phenotype and markers of disease severity outcome, including MELD score and readmission rates.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Age 18 or over.
  • Diagnosis of alcohol-associated liver disease and alcohol use disorder:
    • The diagnosis of ALD will be determined by a hepatologist based on history of regular and excessive alcohol consumption in the absence of other causes of liver cirrhosis or acute hepatitis, compatible clinical, imaging, and laboratory findings and typical histology on liver biopsy, if performed;
    • The diagnosis of AUD will be determined by a hepatologist and/or addiction psychiatrist based on history obtained that is consistent with DSM-5 diagnostic criteria for AUD (all categories of mild, moderate, and severe considered eligible).
  • Capacity to provide consent.
  • Access to a smartphone, cellular data, and wireless internet connection through the smartphone device.

Exclusion Criteria:

  • Inability to respond to smartphone-delivered questionnaires.
  • Inability to send and receive text messages.
  • Moderate to severe hepatic encephalopathy, defined by West-Haven score of 3 or higher.
  • Severe psychiatric comorbidity, not controlled on pharmacological or non-pharmacological therapy.

Eligibility last updated 2/23/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Vijay Shah, M.D.

Abierto para la inscripción

Contact information:

Tiffany Wu M.D.

Wu.Tiffany@mayo.edu

More information

Publicaciones

Publications are currently not available